Carrasquilla, M., Alvis-Zakzuk, N.J., Zakzuk Sierra, J., Gómez De la Rosa, F., Beltran, C., Rojas, M., Prieto, E., Yen, G., Parellada, C., Pavelyev, A., Monsanto, H., De La Hoz, F., and Alvis Zakzuk, N.R.
We assessed the public health and economic impact of adding males to the existing female-only quadrivalent HPV vaccine (4vHPV) program in Colombia, analyzing different gender-neutral vaccination (GNV) vaccine coverage rates (VCRs). The predicted health outcomes included HPV 6/11/16/18-related disease and deaths averted [cervical intraepithelial neoplasia, cervical, vaginal, vulvar, penile, anal and head and neck cancers, genital warts (GW), and recurrent respiratory papillomatosis], direct healthcare cost prevented by vaccination, and incremental cost-effectiveness ratios (ICERs). [Extracted from the article]